Newly Diagnosed Acute Promyelocytic Leukemia by Avvisati, Giuseppe
Mediterr J Hematol Infect Dis 2011; 3; Open Journal System 
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
How I Treat
Newly Diagnosed Acute Promyelocytic Leukemia
Giuseppe Avvisati 
Unità  Operativa  Complessa  di  Ematologia,  Trapianto  di  cellule  staminali,  Medicina  trasfusionale  e  Terapia 
cellulare. Università Campus Bio-Medico, Roma, Italy 
Correspondence to: Giuseppe Avvisati, MD, PhD
00128 Roma, Italy. Tel: +39.06.225411613, Fax: +39.06
Competing interests: The authors have declared th
Published: Decmber 20, 2011
Received: December 16, 2011
Accepted: December 17, 2011
Mediterr J Hematol Infect Dis 2011, 3(1): e201
This article is available from:  http://www.mjhid.org/article/view/9777
This  is  an  Open  Access  article  distributed  under  the  terms  of  the  Creative  Commons  Attribution  License
(http://creativecommons.org/licenses/by/2.0
provided the original work is properly cited
Abstract. Acute promyelocytic leukemia (APL) represents a medical emergency with a high rate of 
early  mortality.  As  a  consequence,  as  soon  as  the  diagnosis  is  suspected  based  upon  cytologic 
criteria, it is necessary to start all-
with newly diagnosed APL, induction therapy with ATRA plus anthracycline based chemotherapy 
is recommended. At present the combination of arsenic trioxide plus ATRA should be considered 
for  patients  who  are  not  candidates  for  anthracycline
patients with APL aged < 60 years who achieve a CR with induction, I recommend 3 intensive 
courses of consolidation chemotherapy associated to ATRA,
at diagnosis.  In patients treated with  a very intensive consolidation chemotherapy maintenance 
treatment can be omitted. However If a maintenance treatment has to be adopted I suggest the use 
of intermittent ATRA  for 15 days every 3  mont
associated to chemotherapy. Moreover, taking into account the medical literature, a reduced dosage 
of ATRA ( 25 mg/m
2) in pediatric patients and a consolidation chemotherapy of reduced intensity 
in elderly patients is recommended. Furthermore,
should be reserved to the coagulopathy and to the appearance of the differentiation syndrome. 
Finally, PCR for the PML/RARA fusion gene on a bone marrow specimen every three 
two years, and then every six months for additional three years are needed during the follow
Introduction. Acute  promyelocytic  leukemia  (APL) 
represents a biological and clinical distinct variant of 
acute  myeloid  leukemia  (AML)  characterized  by  a 
typical  blast  cell  morphology,  presence  of  a  severe 
coagulopathy,  high  sensitivity  to  induction 
chemotherapy  with  anthracycline  drugs  and  by  the 
presence  of  the  specific  chromosome  translocation  t 
(15;17)  in  the  leukemic  blasts.
1-4 This  translocation 
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Acute promyelocytic leukemia (APL) represents a medical emergency with a high rate of 
early  mortality.  As  a  consequence,  as  soon  as  the  diagnosis  is  suspected  based  upon  cytologic 
- trans retinoic acid (ATRA) treatment without delay. For patients 
with newly diagnosed APL, induction therapy with ATRA plus anthracycline based chemotherapy 
is recommended. At present the combination of arsenic trioxide plus ATRA should be considered 
ients  who  are  not  candidates  for  anthracycline-based  therapy.  For  pediatric  and  adult 
patients with APL aged < 60 years who achieve a CR with induction, I recommend 3 intensive 
courses of consolidation chemotherapy associated to ATRA, targeted on the basis
at diagnosis.  In patients treated with  a very intensive consolidation chemotherapy maintenance 
treatment can be omitted. However If a maintenance treatment has to be adopted I suggest the use 
of intermittent ATRA  for 15 days every 3  months for a period of  2 years
associated to chemotherapy. Moreover, taking into account the medical literature, a reduced dosage 
) in pediatric patients and a consolidation chemotherapy of reduced intensity 
nts is recommended. Furthermore, in order to maximize survival, careful attention 
should be reserved to the coagulopathy and to the appearance of the differentiation syndrome. 
Finally, PCR for the PML/RARA fusion gene on a bone marrow specimen every three 
two years, and then every six months for additional three years are needed during the follow
Acute  promyelocytic  leukemia  (APL) 
a biological and clinical distinct variant of 
acute  myeloid  leukemia  (AML)  characterized  by  a 
typical  blast  cell  morphology,  presence  of  a  severe 
coagulopathy,  high  sensitivity  to  induction 
chemotherapy  with  anthracycline  drugs  and  by  the 
pecific  chromosome  translocation  t 
This  translocation 
involves the retinoic acid receptor
on chromosome 17 and the PML (for promyelocytic) 
gene on chromosome 15 giving origin to the chimeric 
genes PML/ RARA and RARA/PML.
French-American-British  (FAB)  classification  system 
APL was classified as AML
classification  system,  is  currently  classified  as  acute 
promyelocytic leukemia with t(15;17)(q22;q12);PML
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Acute promyelocytic leukemia (APL) represents a medical emergency with a high rate of 
early  mortality.  As  a  consequence,  as  soon  as  the  diagnosis  is  suspected  based  upon  cytologic 
ans retinoic acid (ATRA) treatment without delay. For patients 
with newly diagnosed APL, induction therapy with ATRA plus anthracycline based chemotherapy 
is recommended. At present the combination of arsenic trioxide plus ATRA should be considered 
based  therapy.  For  pediatric  and  adult 
patients with APL aged < 60 years who achieve a CR with induction, I recommend 3 intensive 
targeted on the basis of the risk group 
at diagnosis.  In patients treated with  a very intensive consolidation chemotherapy maintenance 
treatment can be omitted. However If a maintenance treatment has to be adopted I suggest the use 
hs for a period of  2 years, rather than ATRA 
associated to chemotherapy. Moreover, taking into account the medical literature, a reduced dosage 
) in pediatric patients and a consolidation chemotherapy of reduced intensity 
in order to maximize survival, careful attention 
should be reserved to the coagulopathy and to the appearance of the differentiation syndrome. 
Finally, PCR for the PML/RARA fusion gene on a bone marrow specimen every three months for 
two years, and then every six months for additional three years are needed during the follow-up.
involves the retinoic acid receptor-alfa (RARA) gene 
on chromosome 17 and the PML (for promyelocytic) 
gene on chromosome 15 giving origin to the chimeric 
RA and RARA/PML.
5-7 In the  older 
British  (FAB)  classification  system 
APL was classified as AML-M3 while, in the WHO 
classification  system,  is  currently  classified  as  acute 
promyelocytic leukemia with t(15;17)(q22;q12);PML-Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
RARA.
8
Without treatment, APL is the most malignant form 
of  AML  with  a  median  survival  of  less  than  one 
month
9-11 and  many  patients  die  before  reaching  an 
experienced  hematologist.  However,  modern  therapy 
has dramatically changed its prognosis and APL is now 
associated with the highest proportion of AML patients 
who are cured of their disease. In this article I will give 
my personal opinions about the modern treatment of 
newly diagnosed APL, a treatment distinct from that of 
other types of AML.
12-13
What to do in case of suspected APL? This is the 
first question that I would like to address because, as in 
the other AML, all patients with suspected APL should 
undergo several studies to evaluate disease extent and 
comorbidities;  however,  these  studies  should  not 
interfere  with  the  rapid  initiation  of  ATRA-based 
therapy. In fact, APL represents a medical emergency 
with  a  high  rate  of  early  mortality,  due  mainly  to 
hemorrhagic  complications  from  a  characteristic 
coagulopathy. Therefore, the first golden rule that has 
to  be  followed  as  soon  as  the  diagnosis  of  APL  is 
suspected based  upon  cytologic  criteria  is:  to 
immediately start treatment with all-trans retinoic acid 
(ATRA)  without  delay,  even  before  definitive 
(cyto)genetic  confirmation  of  the  diagnosis has  been 
made.
14 If the diagnosis is not confirmed, ATRA can 
always be discontinued and treatment changed to that 
used for other types of AML. 
What is the best induction therapy? In the following 
sections I will describe some of the multiple trials that 
have  investigated  the  optimal  means  of  combining 
ATRA and chemotherapy during induction.
ATRA alone. ATRA was firstly utilized as single agent 
to  treat  APL  by  a  Chinese  group  from  Shangai  in 
1988.
15 However, it was soon evident that remissions 
induced by ATRA therapy alone were short-lived with 
a median duration of less than 6 months. 
ATRA  plus  Chemotherapy. Very  soon,  after  the 
experience of the Shangai group, ATRA was combined 
with  anthracycline-based  chemotherapies.  The 
concurrent  administration  of  ATRA  plus  cytotoxic 
chemotherapies produced a  complete remission (CR) 
rate in more than 80 percent of patients of all ages with 
newly  diagnosed  APL
16-20 and  almost  all  treatment 
failures were due to early mortality,
21 whereas primary 
resistance  to  the  combination  of  ATRA  and 
chemotherapy was unusual except for patients with the 
rare t(11;17) who must generally be treated as the other 
AML. 
The  concurrent  administration  of  ATRA  plus 
chemotherapy  was  supported  by  randomized  trials 
demonstrating that patients who received both ATRA 
and  chemotherapy  had  superior  rates  of  CR  and 
disease-free survival when compared with patients who 
received  chemotherapy  alone.
16-17 Moreover,  the 
duration  of  coagulopathy  was  reduced  when  ATRA 
was  added  to  induction  chemotherapy.
16,22-23
Furthermore, the addition of chemotherapy to ATRA 
helped to control hyperleukocytosis that occurred more 
frequently when ATRA was used alone. Therefore, the 
combination  of  ATRA  plus  chemotherapy  limits 
complications that may occur when either agent is used 
alone.
Timing  of  Chemotherapy. Several  trials  have 
demonstrated better  outcomes when  chemotherapy is 
administered  with  ATRA  during  induction 
(simultaneous  administration)  rather  than  postponing 
chemotherapy  until  a  CR  is  achieved  with  ATRA 
(sequential administration). The largest of these trials 
was  a  prospective  randomized  trial  comparing 
sequential and simultaneous administration of ATRA 
and  chemotherapy  in  more  than  400 patients  with 
newly diagnosed APL.
16 While the rates of CR were 
similar  in  the  two treatment  groups,  patients  who 
received simultaneous therapy had significantly lower 
rates of relapse at two years (6 versus 16 percent) and a 
non significant lower rates of differentiation syndrome 
(11 versus 20 percent) when compared with those who 
received sequential therapy. After a median follow-up 
of 10 years, this lower relapse rate persisted, but lost its 
statistical  significance  (13  versus  22  percent, 
respectively).
24
Choice  of  Chemotherapy. For  many  years 
anthracyclines  have  been the  mainstays  of  induction 
therapy  for  APL;  the  observation  of  an  exquisite 
sensitivity of APL to daunorubicin, originally reported 
by  Bernard  et  al in  1973,
25 was  confirmed  and 
extended  to  other  anthracyclines  in  the  1980s.
26-29
Unlike other AML subtypes, these agents were able to 
produce  long-lasting  remissions  when  used  as 
induction  monotherapy  for  APL. A  possible 
explanation  of  such  high  sensitivity  of  APL  to 
anthracycline drugs maybe the low expression of the 
multidrug-resistance  related  protein  (MDR-1)  on  the 
membrane  of  leukemic  cells.
30-33 Therefore,  because 
ATRA  therapy  alone  induced  short-lived remissions,
anthracycline-based  regimens  associated  to  ATRA 
have been administered to patients with APL. The best 
results have been obtained when ATRA was combined 
with  daunorubicin  and  cytarabine
16,34-37 or  with 
idarubicin alone.
20,38-40 These trials have reported a CR 
rate  ranging  from  80%  to  95%.  Moreover,  a 
prospective, randomized trial that investigated whether Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
cytarabine  could be  eliminated  from  this  regimen 
found that patients who received cytarabine had similar 
CR  rates  but  fewer  relapses  and  improved  survival, 
when  compared  with  patients  who  did  not  receive 
cytarabine.
37,41 However,  the  PETHEMA  group  has 
produced excellent outcomes with successive induction 
and  consolidation  cycles  using  idarubicin  and 
mitoxantrone  without  the  use  of  cytarabine.
19 A 
retrospective  analysis  of  patients  treated  with  AIDA
induction reported a CR rate of 91 percent.
42 The most 
common causes of early mortality were hemorrhage (5 
%) and infection (2.3 %) with lethal bleeding occurring 
most  frequently  in  the  first  week  of  therapy  while 
deaths  due  to  infection  were  spread  throughout  the 
course of induction treatment.
How  I  will  induce  hematological  CR in  newly 
diagnosed APL? Taking into account all the previous 
observations, for patients with newly diagnosed APL, I 
recommend  induction  therapy  with  ATRA  plus 
anthracycline-based  chemotherapy  rather  than 
treatment with either ATRA or chemotherapy alone. In 
Italy, the combination of ATRA with the anthracycline 
Idarubicine (AIDA), without the use of cytarabine, is 
the preferred induction treatment of newly diagnosed 
APL. This induction treatment was firstly proposed by 
the GIMEMA group
43 and consist of daily ATRA (45 
mg/m
2/day orally divided into two doses), starting on 
day zero, and four days of idarubicine (12 mg/m
2 days 
1,3,5,7). Children and adolescents (< 20 years) should 
receive a reduced dose of ATRA (25 mg/m
2 per day) in 
combination with chemotherapy.
40 ATRA is continued 
throughout the  period of pancytopenia  until a  CR is 
obtained.  This  regimen  requires  transfusion  support 
and  antibiotics  as  needed.  Daily  laboratory  testing 
generally includes a complete blood count, renal and 
liver  functions,  glucose  and  electrolytes.  Calcium, 
phosphorus, and uric acid levels should be monitored 
until  normal.  Coagulation  parameters,  should  be 
monitored  closely.  Common  non-hematologic  side 
effects  include stomatitis, reversible alopecia,  nausea 
and  vomiting.  Beside minor  drug  toxicities  due  to 
ATRA  such  as:  headache;  nasal  stuffiness,  dry  red 
skin,  chapped  lips,  transient  elevations  in  serum 
aminotransferases  and  bilirubin,  and 
hypertriglyceridemia there are two serious and specific 
complications  that  can  result  from  ATRA  treatment: 
differentiation syndrome and hyperleukocytosis. These 
complications are discussed in more detail below. 
Consolidation  treatment. Generally,  with  induction 
therapy, 90 percent of patients with newly diagnosed 
APL  achieve  a  hematological  complete  remission 
(CR). However, to avoid a relapse in all these patients, 
additional  cytotoxic  consolidation  therapy  is  needed. 
The  aim  of  consolidation  therapy  is  to  eliminate 
leukemia  cells  that  survived  induction  therapy  and 
were not detectable by conventional tests. Therefore, 
by consolidation treatment, patients with morphologic 
and cytogenetic CR after induction will be converted 
into  a  more  durable  molecular  remission  and 
eventually a cure. Several studies have shown a highly 
significant  correlation  between  patients’  molecular 
status  detected  at  the  end  of  consolidation  and 
subsequent outcome.
44,45This is the reason why current 
guidelines  have established  that  molecular  remission 
must be a therapeutic objective in APL.
46
How  should  APL  be  consolidated? A  consolidation 
treatment with 2-3 intensive cycles of an anthracycline 
(daunorubicin  or  idarubicin)  based  chemotherapy 
should  be  adopted  as  standard  in  this  phase  of 
treatment  because  it  is  able  to  produce  a  PCR-
negativity in about 99% of APL. 
Can post-remission therapy be risk-adapted? Patients 
with APL can be risk-stratified for relapse into three 
groups  based  upon  WBC  and  platelet  counts  at 
diagnosis:
47
 Low-risk disease (WBC count <10,000/L and 
platelets >40,000/L).
 Intermediate-risk  disease  (WBC  count 
<10,000/L but platelets <40,000/L).
 High-risk disease (WBC count >10,000/L and 
platelets <40,000/L).
Using current regimens, there is little difference in 
outcomes between the  low-risk  and  intermediate-risk 
groups. 
A PETHEMA prospective trial examined the use of 
risk-adapted consolidation therapy in APL patients in 
first  CR  after  induction  with  AIDA  regimen.
48 The 
results revealed that patients with low- or intermediate-
risk disease, who received less intensive consolidation,
when compared with historical matched controls, had 
shorter durations of neutropenia and thrombocytopenia 
while  patients  with  high-risk  disease  who  had 
cytarabine  added  to  consolidation  demonstrated  a 
significantly  lower  rate  of relapse  at  three  years (11
versus 26 percent). 
A second prospective trial of risk-adapted therapy 
by the GIMEMA group
39 assigned patients with low-
or intermediate-risk disease to consolidation with three 
anthracycline-based courses, while patients with high-
risk  disease  had  cytarabine-based  consolidation.  In 
particular,  patients  with  low-/intermediate-risk
received  the  same  3  consolidation  courses  as  in  the 
AIDA-0493
40 but  with  omission  of cytarabine from 
courses 1 and 3 and omission of etoposide from course 
2; patients in the high-risk group received the identical 
3 cycles as in the AIDA-0493.
40 In addition, distinct Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
from the AIDA-0493, oral ATRA at 45 mg/m
2 per day 
for 15 days was added in the AIDA-2000 at the start of 
each  consolidation  course  for  all  risk  groups.  When 
compared  with  historical  matched  controls,  patients 
with  low- and  intermediate-risk  disease  had 
significantly improved disease-free survival rates at six 
years (86 versus 77 percent) and a lower cumulative 
incidence of relapse (11 versus 20 percent), but similar 
rates  of  overall  survival  (89  versus  85  percent). 
Patients  with  high-risk  disease  had  superior  overall 
survival at six years (83 versus 61 percent), disease-
free  survival  (85  versus  50  percent),  and  a  lower 
cumulative incidence of relapse (9 versus 50 percent).
These two studies indicate that risk adapted therapy 
is  feasible and  save  even though  a  longer follow-up 
and  more  studies  of  these  approaches  are  needed 
before  risk-adapted  therapy  can  be  widely 
implemented. 
Evaluation of the response after consolidation. The 
aim  of  APL  treatment  is  the  achievement  of  a 
molecular complete remission (CRm) at the end of the 
consolidation phase. CRm is defined by the absence of 
the  PML-RARA  fusion  transcript  using  RT-PCR 
methods.  Therefore,  after  the  completion  of 
consolidation,  the  response  to  treatment  must  be 
evaluated with a bone marrow aspirate tested for the 
PML-RARA  fusion  transcript  using  reverse 
transcription  polymerase  chain  reaction  (RT-PCR), 
with a sensitivity threshold of at least 10
-4.
46 Because a 
CRm takes time to achieve, a premature evaluation of 
CRm by RT-PCR should not be attempted immediately 
after  completion  of  induction  treatment  to  avoid  a 
misleading interpretation of response failure. Patients 
who  achieve  CRm  after  completion  of  consolidation 
should  proceed  directly  to  maintenance  therapy. 
Patients who result positive for the PML-RARA fusion 
gene at the end of the planned consolidation sequence 
should have a second bone marrow aspirate with RT-
PCR testing repeated in four weeks. If this second test 
is  negative, the  patient  may  proceed  to  maintenance 
therapy.  If  the  second  RT-PCR  is  still  positive,  the 
patient  should  proceed  to  treatment  for  resistant 
disease. 
What  about  the  use  of  maintenance  treatment  in 
Molecularly negative APL after Consolidation? The 
first  prospective  randomized  trials  of  ATRA  plus 
chemotherapy demonstrated that, when compared with 
observation, patients assigned to  ATRA maintenance 
had superior rates of disease-free survival at five years 
and  a  lower  10-year  cumulative  incidence  of 
relapse.
24,35 The  main  side  effects  of  maintenance 
therapy are cytopenias and liver enzyme elevation
24
easily managed in most patients with dose adjustments. 
However,  two  recent  randomized  trials  dealing  with 
maintenance therapy after the achievement of a CRm
have  demonstrated that  maintenance  therapy  in  APL 
may  not  be  necessary.
40,49 In  both  these  studies  all 
patients  were  in  CRm  following  consolidation  and 
have received a more intensive consolidation therapies 
than those utilized in early studies.  In particular, the 
JALSG study involving 175 patients in CRm following 
induction  and  three  cycles  of  consolidation 
chemotherapy, the addition of six courses of intensive 
maintenance  chemotherapy,  as  compared  with 
observation only, unexpectedly conferred significantly 
poorer  six-year  disease-free  survival  (63  versus  80 
percent) and overall survival (86 versus 99 percent).
49
Moreover,  in  the  GIMEMAstudy  including  586 
patients  with  newly  diagnosed  APL  in  CRm  after 
induction with ATRA and idarubicin followed by three 
cycles of intensive consolidation therapy, maintenance 
did not appear to improve disease-free survival.
40 Until 
additional  data  are  available,  my  personal  opinion 
about  the  use  of  maintenance  treatment  is  to  avoid 
maintenance treatment in APL, provided that patients 
are in CRm and have received an intensive 3 courses 
consolidation  phase,  or  to  use  ATRA  45  mg/m
2 PO 
daily on an intermittent schedule (15 days every three 
months) for 2 years. 
Monitoring response after consolidation. Once a CRm 
is  achieved patients  must  be followed, using  bone 
marrow aspirate samples, with RT-PCR for the PML-
RARA fusion transcript every 3 months during the first 
2-3  years and  then  every  6  months  for  additional  2 
years in order to monitor for molecular relapse. If CRm 
is lost, the patient undergoes bone marrow evaluation 
for  confirmation  within  two  weeks  and  proceeds  to 
therapy for relapsed disease. 
Complications  that  are  specific  to  patients  with 
APL.
Control of coagulopathy. APL is characterized by the 
presence  of  a  severe  coagulopathy  involving  the 
coagulation  and  fibrinolityc  systems  with  the 
participations  of  some  proteolytic  enzyme  and  some 
cytokines.
22 Therefore, treatment of the coagulopathy 
associated with APL may be difficult and should be 
managed  expectantly.  Coagulation  parameters 
(fibrinogen, FDP/XDP, PT, aPTT, and platelet counts) 
should  be  monitored  closely.  Our  approach  to  the 
control of coagulopathy is mainly based upon our own 
clinical  experience  and  observations  and  may  be 
summarized as follows:
 Transfusions of platelets or fresh frozen plasma 
are  traditionally  used  to  maintain  the  platelet 
count above 20,000 to 30,000/L and the plasma Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
fibrinogen concentration above 150 mg/dL.
 Heparin must not be used for prophylaxis in this 
setting. 
 In case of life-threatening bleeding, inhibitors of 
fibrinolysis should be considered. 
 Invasive  procedures  such  as  central  venous 
catheterization,  lumbar  puncture,  and 
bronchoscopy  should  be  avoided  before  and 
during induction remission.
Differentiation  syndrome. This  syndrome, previously 
named "retinoid acid syndrome", occurs in 10-25% of 
APL  patients  within  2  to  21  days  after  initiation  of 
treatment and is seen more frequently in patients with a 
high  white  blood  cell  count  at  diagnosis.
50-51 It  is 
characterized  by  fever,  peripheral  edema,  pulmonary 
infiltrates,  hypoxemia,  respiratory  distress, 
hypotension,  renal  and  hepatic  dysfunction,  and 
serositis resulting in pleural and pericardial effusions. 
The  symptoms  of  fever,  hypotension,  dyspnea,  and 
pulmonary infiltrates can mimic sepsis. Sometimes, the 
syndrome is accompanied by hyperleukocytosis. Early 
recognition  and  aggressive  management  with 
dexamethasone therapy (10 mg IV every 12 hours for 
three or more days) has been effective in most patients. 
After  respiratory  distress  is  established  temporary 
cessation of ATRA or ATO, leukapheresis, or prompt 
institution  of  cytotoxic  chemotherapy  have  not  been 
effective. ATRA or ATO can be restarted in most cases 
once the syndrome has resolved. 
Hyperleukocytosis. The marked increase in WBC count 
due  to  the  rapid  maturation  induced  by  ATRA  of  a 
large mass of leukemic cells, may result in leukostasis 
and  management  is  controversial.  However,  because 
the  most  current  remission  induction  regimens  now 
combine  ATRA  with  cytotoxic  chemotherapy,  the 
frequency of hyperleukocytosis has decreased. Despite 
patients with an elevated WBC count have a similar 
rate of complete remission compared with those with a 
normal  or  decreased  white  blood  cell  (WBC) count, 
however  they  have  a  higher  rate  of  relapse  and  are 
more likely to develop the differentiation syndrome.
51-
52
Pseudotumor  cerebri. Idiopathic  intracranial 
hypertension  (IIH),  commonly  called  pseudotumor 
cerebri,  can  complicate  the  treatment  of  APL  with 
ATRA.
53 It  is  more  common  in  children  and 
adolescents treated with ATRA  and the  incidence in 
this population decreased with the use of lower dose 
ATRA  (25  mg/m2  /day).  The  diagnosis  of  IIH  is 
suspected  in  patients  with  headache,  papilledema, 
and/or  vision  loss.  Evaluation  includes  a  physical 
examination  including  lumbar  puncture,  cerebral 
imaging  studies  (computed  tomography  or  magnetic 
resonance)  and  fundus  oculi. The  diagnosis  is 
confirmed  in  patients  with  increased  intracranial 
pressure,  normal  cerebrospinal  fluid,  and  negative 
cerebral  imaging  studies.  If  symptoms  persist, 
therapeutic  options  include  the  temporary 
discontinuation or dose reduction of ATRA, analgesics, 
and/or the administration of steroids and acetozolamide
Management  of  special  situations. Some patients 
with  APL  such  as  pregnant  women,  therapy-related 
APL, those with genetic variations of APL as well as 
elderly  and  pediatric  patients  require  special 
consideration.
Pregnant women. Patients diagnosed with APL during 
pregnancy pose a distinct challenge requiring a team 
approach  with  a  hematologist,  obstetrician,  and 
neonatologist. The treatment approach depends largely 
upon the trimester of pregnancy during which APL is 
diagnosed.
54-55
First trimester. Both ATRA and ATO are considered to 
be  highly  teratogenic  and  are  contraindicated  during 
the first trimester of pregnancy. Therefore, if elective 
termination  of  the  pregnancy  is  unacceptable  to  the 
patient,  the  only  available  treatment  option  is  the 
administration  of  chemotherapy  alone.  If  treatment 
with chemotherapy alone is chosen, daunorubicin may 
be  the  preferred  anthracycline  for  pregnant  women 
because  there  is  greater  experience  with  this  drug 
during pregnancy.
54-55 If a remission is achieved and 
the  pregnancy  continues  normally,  ATRA  may  be 
added during the second or third trimester. 
Second  or  third  trimester.  Two  main  options  are 
available for women who are diagnosed with APL in 
the second or third trimester of pregnancy:
 Remission  induction  with  ATRA  alone  and 
chemotherapy postponed until after delivery.
 Simultaneous  administration  of  ATRA  plus 
chemotherapy.
The  simultaneous  administration  of  ATRA  plus 
chemotherapy offers the best chance of cure. Vaginal 
delivery  is  generally  preferred  since  it  is  associated 
with  a  reduced  risk  of  bleeding.  After  delivery, 
breastfeeding  is  contraindicated  while  on 
chemotherapy or ATO.
Therapy  related  APL  (t-APL). Patients  with  t-APL 
appear to have a similar prognosis as de novo APL and 
benefit from standard APL therapy.
56 Therefore, most 
patients with t-APL can be treated with standard APL 
therapy.  In  patients  with  a  history  of  anthracycline 
exposure or cardiac impairment that limits their ability 
to  receive  further  treatment  with  anthracyclines, 
alternative regimens, such as ATRA plus ATO may be Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
used. 
Genetic Variations of APL. More than 90% of patients 
with  APL  have  t(15;17)(q22;q12)  translocation 
resulting  in  the  PML/RARA  fusion  gene.  However, 
very  rarely  have  been  described  alternative  fusion 
genes resulting in leukemias classified as "AML with a 
variant  RARA  translocation"  and  some  of  these 
conditions are sensitive to ATRA therapy while others 
are not.
In  general,  patients  with  alternative  fusion  genes 
ATRA-sensitive are treated with standard ATRA-based 
therapy,  as  described  above.  Patients  with  variants 
known  to  be  resistant  to  ATRA  are  treated  with 
standard AML induction therapy. The following are the 
alternative fusion genes identified as ATRA-sensitive:
 NuMA/RARA and t(11;17)
 NPM1/RARA and t(5;17)
 FIP1L1/RARA
Whereas,  the  following  are  ATRA-resistant 
variants:
 STAT5b/RARA and interstitial chromosome 17 
deletion 
 PLZF/RARA and t(11;17) 
In  case  APL  patients  have  additional  cytogenetic 
abnormalities,  as  trisomy  8,  or  particular  molecular 
abnormalities (gene mutations in FLT3) the prognosis 
is not worsened and they are considered to have the 
same prognosis as standard APL. 
Elderly APL patients. Because of the possibility of an 
increased therapy-related toxicity, elderly patients (60 
years or older) are usually treated with less intensive 
regimens..
57,58
Pediatric APL patients. So far only few studies, have 
reported  therapeutic  results  using  ATRA  plus 
Chemotherapy in pediatric patients. Compared to the 
disease in  adults, APL diagnosed in  childhood more 
frequently presents with hyperleukocytosis. In spite of 
that, the outcome results are comparable. With the aim 
of decreasing the risk of pseudotumor cerebri, the dose 
of ATRA in this setting has generally been reduced to 
25 mg/m
2 without compromising the results.
59-61
Do  I  have  to  use  CNS  prophylaxis  in  APL?
Generally in newly diagnosed APL patients the central 
nervous system (CNS) involvement is very rare if not 
absent.  As  a  consequence,  CNS  has  been  never 
routinely used. However, recently an increased number 
of  CNS  relapses  have  been  reported  suggesting  a 
possible association with ATRA use. This correlation, 
however, was not demonstrated by a large retrospective 
study of the GIMEMA group carried out in two cohorts 
of  patients  included  in  two  successive  therapeutic 
protocols utilizing or not ATRA during the induction 
treatment.
62 It is therefore possible that the increased 
survival observed in APL patients treated with ATRA-
based regimens,may account for the apparently higher 
prevalence of extramedullary  relapse, including CNS 
relapse.  As  a  consequence,  while  there  is  a  general 
consensus  to  avoid  CNS  prophylaxis  for  patients 
without hyperleukocytosis (in whom the risk of CNS 
relapse  is  extremely  low), it  is  my  personal  opinion 
that because  the  majority  of  CNS  relapses  occur  in 
patients with hyperleukocytosis, CNS prophylaxis with 
methotrexate  12  mg  (total  dose)  and  6-methyl 
prednisolone 40 mg (total dose) is needed for patients 
in this particular high-risk setting. Moreover, because
lumbar puncture at presentation and during induction is 
extremely  hazardous,  CNS  prophylaxis  should  be 
performed only after the achievement of CR.
When  Hemopoietic  Stem  Cells  Transplantation 
(HSCT) is needed? For those APL patients who are in 
the  first  molecular  remission  at  the  end  of 
consolidation, considering the high cure rate obtained 
using  upfront  ATRA  and  chemotherapy,  there  is  no 
role for HSCT. On the contrary, for the small fraction 
of patients with persistent minimal residual disease at 
the end of consolidation, considering the overall poor 
prognosis  of  this  subset  of  patients,
63 ATO  and/or 
Gemtuzumab  (GO) followed  by  HSCT  should  be 
considered.  Allogeneic  HSCT  is  the  recommended 
choice  for  patients  with  an  available  HLAidentical 
donor, whereas autologous HSCT is a valid alternative 
for  patients  ineligible  for  allogeneic  transplant  even 
though  the  achievement  of  PCR-negativity  prior  to 
autologous HSCT is a mandatory requisite.
The  role  of  Arsenic  Trioxide  (ATO)  in  newly 
diagnosed APL. ATO alone or in  combination with 
ATRA, is  capable of producing CRm in  previously 
untreated APL.
64-69
When to use ATO plus ATRA as induction treatment in 
newly diagnosed APL?  At present, this combination of 
ATO plus ATRA should be reserved to APL patients 
who  are  not  candidates  for  anthracycline-based 
therapy.  However,  some  studies  are  evaluating  the 
possibility  of avoiding  chemotherapy  and  using  this 
type  of  combination  in  low  risk  (WBC  count 
<10,000/mm
3 and  platelets  >40,000/mm
3)  APL 
patients. 
Moreover, the combination of ATO plus ATRA has 
not  been  directly  compared  with  ATRA  plus 
anthracycline-based chemotherapy. Therefore, for most 
patients with newly diagnosed APL, I prefer ATRA plus 
chemotherapy as induction treatment mainly because 
of  the  greater  experience  and  longer  follow-up  ofMediterr J Hematol Infect Dis 2011; 3: Open Journal System
patients treated with this combination. However, ATO 
plus  ATRA  may  be  an  excellent  option  for  patients, 
such  as  older  adults,  who  are  not  able  to  tolerate 
anthracycline-based therapy.
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Conclusions. Acute  promyelocytic  leukemia  (APL) 
represents  a  medical  emergency  with  a  high  rate  of 
early mortality. It is necessary to start ATRA treatment 
without  delay  as  soon  as  the  diagnosis  is  suspected 
based upon cytologic criteria. For patients with newly 
diagnosed APL, I recommend induction therapy with 
ATRA  plus  anthracycline  based  chemotherapy.  At 
present the combination of arsenic trioxide plus ATRA 
should  be  considered  for  patients  who  are  not 
candidates  for  anthracycline-based  therapy.  For 
pediatric and adult patients with APL aged < 60 years 
who  achieve  a  CR  with  induction,  I  recommend  3 
courses of a consolidation chemotherapy associated to 
ATRA, targeted  on  the  basis  of  the  risk  group  at 
diagnosis. In those patients who achieve CRm after a 
risk adapted consoldiatation treatment, I do not suggest
the  use  of  maintenance  therapy.  However,  if  a 
maintenance treatment has to be adopted I suggest the 
use of intermittent ATRA for 15 days every 3 months 
for a period of 2 years. Moreover, I suggest a reduced 
dosage of ATRA (25 mg/m
2) in pediatric patients and a 
consolidation  chemotherapy  of  reduced  intensity  in 
elderly  patients  with  the  possibility  of  using  the 
combination of ATO+ATRA in patients who are not
candidates  to  anthracycline-based  therapy. 
Furthermore, careful  attention  in  order  to  maximize 
survival should be reserved to the coagulopathy present 
in APL using transfusions of platelets to maintain the 
platelet count above 30,000/L or higher associated to 
the immediate initiation of treatment with ATRA plus 
chemotherapy.  Careful  attention  should  be  reserved 
also to the appearance of the differentiation syndrome 
because  the  early  recognition  and  the  immediate 
treatment  with  dexamethasone  (10  mg  IV  every  12 
hours for three or more days), along with temporary 
cessation  of  ATRA  is  paramount.  ATRA  can  be 
restarted once the syndrome has resolved. Finally, PCR 
for  the  PML/RARA  fusion  gene  on  a  bone  marrow 
specimen every three months for two years, and then 
every six months for two years are needed during the 
follow-up.
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